# US 2015/0104441 A1 · Identification of disease-driving antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104441 A1
- Document ID: US20150104441A1
- Status: Published application
- Kind: A1
- Application number: 14/512,737
- Filed: 2014-10-13
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Oslo Universitetssykehus Hf
- Applicants: Oslo Universitetssykehus Hf
- Inventors: Johanna Olweus; Trygve Holmøy; Andreas Lossius
- Web page: https://patentgrep.com/patent/US20150104441A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/505: {involving T-cells}
- G01N 2800/28: Neurological disorders
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein is technology relating to treating disease and particularly, but not exclusively, to methods for identifying disease-related antigens by assessing T cell receptor gene frequencies in diseased subjects.

## Claims

### Claim 1

A method for identifying a disease-related antigen, the method comprising:
a) sequencing a set of T cell receptor genes from a disease-related sample from a subject having a disease;
b) sequencing a set of T cell receptor genes from a control sample;
c) comparing the T cell receptor gene frequencies of the set of T cell receptor genes from the disease-related sample with the T cell receptor gene frequencies of the set of T cell receptor genes from the control sample to identify T cell receptor genes enriched in the disease-related sample,
wherein the T cell receptor genes enriched in the disease-related sample identify a disease-related antigen associated with the disease.

### Claim 2 (depends on 1)

The method of claim 1 wherein the disease is an autoimmune or inflammatory disease.

### Claim 3 (depends on 1)

The method of claim 1 wherein the T cell genes encode T cell receptor alpha-chain polypeptides and T cell receptor beta-chain polypeptides.

### Claim 4 (depends on 1)

The method of claim 1 wherein the T cell genes encode T cell receptor alpha-chain polypeptides or T cell receptor beta-chain polypeptides.

### Claim 5 (depends on 1)

The method of claim 1 wherein the T cell genes encode the T cell receptor beta chain complementarity determining regions.

### Claim 6 (depends on 1)

The method of claim 1 wherein the T cell genes encode T cell receptor beta chain complementarity determining region 3 (CDR3).

### Claim 7 (depends on 1)

The method of claim 1 wherein the disease-related sample is selected from the group consisting of a tissue sample from the central nervous system, a sample from a disease affected organ, cerebrospinal fluid and synovial fluid.

### Claim 8 (depends on 1)

The method of claim 1 wherein the control sample is a blood sample from the subject.

### Claim 9 (depends on 1)

The method of claim 1 further comprising collecting cell samples from the subject having the disease to provide the disease-related sample.

### Claim 10 (depends on 1)

The method of claim 1 further comprising collecting cell samples from an organ or tissue from the subject having the disease to provide the disease-related sample.

### Claim 11 (depends on 1)

The method of claim 1 wherein the control sample is a blood sample and the method further comprises stimulating the blood sample with a test antigen and a control antigen.

### Claim 12 (depends on 11)

The method of claim 11 further comprising isolating T cells that respond to the test antigen and isolating T cells that respond to the control antigen to provide antigen-responding samples.

### Claim 13 (depends on 12)

The method of claim 12 wherein a disease-related antigen is identified by high frequencies of the same TCR genes in the disease-related sample and an antigen-responding sample.

### Claim 14

A method of identifying a disease-related antigen, the method comprising:
a) contacting a control sample from a subject diagnosed with an inflammatory or an autoimmune disease with a test antigen and a control antigen;
b) isolating T cells from the control sample that respond to said test antigen to provide control sample test-antigen responsive T cells and isolating T cells from the control sample that respond to said control antigen to provide control sample control-antigen responsive T cells;
c) sequencing T-cell receptor genes from said control sample test-antigen responsive T cells to provide control sample test-antigen responsive gene sequences and sequencing T-cell receptor genes from said control sample control-antigen responsive T cells to provide control sample control-antigen responsive gene sequences;
d) isolating T cells from the disease-related sample to provide disease-related T cells;
e) sequencing T-cell receptor genes from said disease-related T cells to provide disease related gene sequences; and
f) comparing the frequency of said control sample test-antigen responsive gene sequences and control sample control-antigen responsive gene sequences with the frequency of said disease-related gene sequences,
wherein the gene sequences enriched in the disease-related sample identify a disease-related antigen associated with the disease.

### Claim 15 (depends on 14)

The method of claim 14, wherein the control sample is a peripheral blood sample.

### Claim 16 (depends on 14)

The method of claim 14 wherein the T cells are CD4+ or CD8+ T cells.

### Claim 17 (depends on 14)

The method of claim 14 wherein the disease is an autoimmune or inflammatory disease.

### Claim 18 (depends on 14)

The method of claim 14 further comprising contacting a control sample from a subject not diagnosed with an inflammatory or an autoimmune disease with the test antigen and the control antigen.

### Claim 19 (depends on 14)

The method of claim 14, further comprising repeating step (a) by contacting a plurality of control samples with a plurality of test antigens and sequencing to provide a reference library for comparison with disease-related gene sequences.

### Claim 20 (depends on 1)

A method of treating a disease comprising an aberrant immunological response to a disease-related antigen, the method comprising identifying the disease-related antigen according to the method of claim 1 and minimizing the immunological response to the disease-related antigen in a patient.
